On July 28, SELLAS Life Sciences Group Inc. declined 14.89% in regular trading, trading at $9.9/share, with turnover of $46.72 million.

On the news front, Sirnaomics announced that the arbitration case against SELLAS Life Sciences at the Hong Kong International Arbitration Centre has received a final ruling. All arbitration claims filed by SELLAS were entirely dismissed. Furthermore, SELLAS is required to bear the opposing party's arbitration-related expenses totaling HKD 7.983 million, due for payment by August 7.

The ruling represents a complete legal defeat for SELLAS, eliminating any potential recovery from the dispute while imposing additional financial obligations. SELLAS Life Sciences Group Inc. is a late-stage clinical biopharmaceutical company focused on developing novel therapies for multiple cancer indications. Its key pipeline candidates include Galinpepimut-S (GPS) for acute myeloid leukemia, currently in a pivotal Phase 3 REGAL trial, and CDK9 inhibitor SLS009, which recently enrolled its first patient in a Phase 2 first-line AML trial.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)